Observational study on vericiguat use in Korean patients with chronic heart failure
Official title: Post-marketing Surveillance Study for Verquvo (Vericiguat) in Korean Heart Failure Patients With Reduced Ejection Fraction
Run by Bayer · NCT06148935 · Data updated 2026-11-12
This study looks at how well vericiguat works and its safety for Korean adults with chronic heart failure who are already receiving their usual treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 1350 (estimated) |
| Sponsor | Bayer Industry-sponsored |
| Locations | 1 site (Multiple Locations) |
| Status | Recruiting |
| Started | November 30, 2023 |
| Main results expected | August 31, 2027 |
| Study ends | October 31, 2027 |
| Registry record updated | July 6, 2026 |
| Trial ID | NCT06148935 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 19 years or older with chronic heart failure and reduced ejection fraction who have been prescribed vericiguat.
✕Probably not a fit
Patients who are pregnant, have contraindications to vericiguat, or are participating in other investigational programs may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to gather data on the use of vericiguat in patients with chronic heart failure with reduced ejection fraction (HFrEF) in a real-world setting in Korea. Participants will receive their usual treatment, and the study will focus on collecting important information regarding the effectiveness and safety of vericiguat. The study targets adults aged 19 and older who have been prescribed vericiguat and meet specific criteria related to their heart failure condition. By analyzing real-world data, the study seeks to enhance understanding of vericiguat's impact on HFrEF management.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the real-world effectiveness of vericiguat for managing chronic heart failure in Korean patients.
How similar studies have gone: Previous studies have shown success with vericiguat in treating heart failure, making this approach relevant and potentially beneficial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult aged 19 years or older * Chronic HF (NYHA functional class II, III, or IV) Reduced left ventricular ejection fraction (\< 45%) within 12 months before enrollment * Worsening of heart failure (hospitalized within 6 months before enrollment or intravenous diuretic therapy without hospitalization within 3 months) * Participants who have been prescribed Verquvo (Vericiguat) as per locally approved label and didn't receive Verquvo (Vericiguat) therapy previously. * Written informed consent from subject or legal representative; assent from subject when appropriate Exclusion Criteria: * Contraindication according to the local authorized label (including known hypersensitivity to the drug substance or any of its components, pregnancy) * Participants participating in an investigational program with interventions outside of routine clinical practice
Where it's running
-
Many Locations
Multiple Locations, South Korea Recruiting
Study contacts
- Study coordinator: Bayer Clinical Trials Contact
- Email: clinical-trials-contact@bayer.com
- Phone: (+)1-888-84 22937
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
S086 tablets for treating chronic heart failure with reduced ejection fraction
This study is testing if S086 tablets can help people with chronic heart failure and reduced ejection fraction feel better compared to a standard treatment.
-
Acoramidis in adults with transthyretin amyloid cardiomyopathy in France
This is an observational study to see how acoramidis is used in everyday care for adults with ATTR‑CM in France and how it affects their quality of life and daily function.
-
How your body handles two forms of elinzanetant in healthy women
This study tests whether a new tablet form of elinzanetant is absorbed and processed by the bodies of healthy women in the same way as an existing capsule form.
-
Heart-risk in older men with advanced prostate cancer treated with enzalutamide or darolutamide
This observational study tests whether heart-related risks differ for older men with advanced prostate cancer treated with enzalutamide or darolutamide.
-
How safe BAY3389934 is when given alone or with aspirin in healthy adults
This study tests BAY3389934, alone and with aspirin, to see if it’s safe and how it affects blood clotting in healthy adults.
-
BAY 3670549 in Atrial Fibrillation: Does it help restore normal rhythm after AF episode?
This study tests BAY 3670549 against a placebo in adults with atrial fibrillation who need electrical cardioversion to see if it helps restore normal heart rhythm and how safe it is.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.